Comparison

(S,R,S)-AHPC-PEG1-NH2 European Partner

Item no. HY-136008-25mg
Manufacturer MedChem Express
CASRN 2241641-57-4
Amount 25 mg
Quantity options 100 mg 25 mg 50 mg
Category
Type Molecules
Specific against other
Purity 98.48
Citations [1]Scheepstra M, et al. Bivalent Ligands for Protein Degradation in Drug Discovery. Comput Struct Biotechnol J. 2019;17:160-176. Published 2019 Jan 25.|[2]Nalawansha DA, et al. PROTACs: An Emerging Therapeutic Modality in Precision Medicine. Cell Chem Biol. 2020;27(8):998-985.
Smiles O=C(N(C[C@H](O)C1)[C@@H]1C(NCC2=CC=C(C(SC=N3)=C3C)C=C2)=O)[C@H](C(C)(C)C)NC(COCCN)=O
ECLASS 10.1 32169090
ECLASS 11.0 32169090
UNSPSC 12000000
Alias VH032-PEG1-NH2
Shipping Condition Room temperature
Available
Manufacturer - Type
Reference compound
Manufacturer - Applications
Cancer-programmed cell death
Manufacturer - Targets
E3 Ligase Ligand-Linker Conjugates
Shipping Temperature
Room temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight
531.67
Product Description
(S, R, S)-AHPC-PEG1-NH2 (VH032-PEG1-NH2) is a synthesized E3 ligase ligand-linker conjugate that incorporates the VH032 based VHL ligand and a linker used in PROTAC technology[1].
Manufacturer - Research Area
Cancer
Solubility
DMSO: 100 mg/mL (ultrasonic)
Manufacturer - Pathway
PROTAC
Isoform
von Hippel-Lindau (VHL)
Clinical information
No Development Reported

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 25 mg
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close